Developing the next generation of nanomedicines.
Development of therapies based on the unique functions of miRNAs with a focus on oncology.
Tackling “undruggable” targets with small molecule inhibitors of intracellular protein-protein interactions.
A new therapeutic approach in immune-oncology, targeting the tumor microenvironment.
A leading Organ-on-a-Chip Company developing human tissue and disease models for tomorrow’s medicines, chemicals and food.
Switching from intravenous-to-oral cancer treatment.
Oncolytic adenovirus technologies.
Enabling endosomal escape of macromolecule therapeutics.
Fully synthetic therapeutic vaccines against cancer and persistent viral infections.
Bispecific antibodies which are targeting solid tumors and blood tumors.
Antibody Drug Conjugate Technologies.
Cristal Therapeutics Initiates Phase 2 Clinical Trial of Innovative CriPec® Nanomedicine Drug Candidate in Ovarian Cancer
InteRNA Presents Expanded Preclinical Proof-of-concept Data on Lead Oncology Development Candidate INT-1B3 at the 14th Annual OTS Meeting